Alnylam Pharmaceuticals Inc at Biotechnology Industry Organization (BIO) CEO & Investor Conference Transcript
Excellent. Well, thank you, Susan, and thank you also to BIO for inviting Alnylam to participate in this conference. Good afternoon, everyone. My name is Josh Brodsky, I'm Director of Investor Relations and Corporate Communications at Alnylam.
I will be making forward-looking statements, and I invite you to review our most recent SEC filings for a fuller discussion of our risk factors.
Now as many of you know, Alnylam has been the leader in advancing RNAi therapeutics as a brand-new class of innovative medicines. RNAi therapeutics is the approach that we've been focused on since we were founded in 2002. At Alnylam, we are proud to have pioneered the translation of RNAi from Nobel Prize-winning science into human clinical trials as well as achieving human proof-of-concept; obtaining positive Phase III data; and now, very importantly, onto the market.
Let me begin with an overview of our recent commercial progress. Last summer, as you probably know, we celebrated the approval and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
